Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 77

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 77
---
 consideration arising from the Flexion Acquisition during the three and six months ended June 30, 2025, respectively. The Company recognized $1.5 million of charges and $2.3 million of gains related to contingent consideration during the three and six months ended June 30, 2024, respectively. See Note 10, Financial Instruments, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value.Restructuring ChargesIn February 2024, the Company initiated a restructuring plan designed to ensure it is well positioned for long-term growth. The restructuring plan included: (i) reshaping the executive team, (ii) reallocating efforts and resources from its ex-U.S. and certain early-stage development programs to its U.S. commercial portfolio in the U.S. market and (iii) reprioritizing investments to enhance key commercial capabilities and expand EXPAREL utilization. The Company recognized $1.0 million and $6.5 million of restructuring charges for the three and six months ended June 30, 2024, respectively, related to employee termination benefits, such as the acceleration of share-based compensation, severance, and, to a lesser extent, other employment-related termination costs, as well as contract termination costs.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 31

The Company’s restructuring charges, including the beginning and ending liability balances, are summarized below (in thousands): Employee Termination Benefits (1)Contract Termination CostsTotalBalance at December 31, 2023$— $— $—    Charges incurred3,220 1,709 4,929    Cash payments made / settled(1,985)(20)(2,005)Balance at December 31, 20241,235 1,689 2,924    Cash payments made / settled(1,095)(1,689)(2,784)Balance at June 30, 2025$140 $— $140 (1) During the year ended December 31, 2024, there was $3.6 million of employee termination benefits related to share-based compensation excluded from the table above as they are non-cash and recorded against additional paid-in capital.In July 2025, the Company announced it decommissioned its 45-liter EXPAREL batch manufacturing suite located at